Slate relies on advertising to support our journalism. If you value our work, please disable your ad blocker. If you want to block ads but still support Slate, consider subscribing.
Already a member? Sign in here
The Risk Too Many People Are Taking With Ozempic
GLP-1 drugs are remarkable. But guidelines and prescribers need to go further in how they evaluate patients.